This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (168)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Osteoporosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Lorenz C. Hofbauer, MD; Michael Schoppet, MD

JAMA. 2004;292:490-495.

Bone resorption by osteoclasts is coupled with bone formation by osteoblasts, and this balanced process continuously remodels and adapts the skeleton. The receptor activator of nuclear factor B ligand (RANKL) has been identified as an essential cytokine for the formation and activation of osteoclasts. The effects of RANKL are physiologically counterbalanced by the decoy receptor osteoprotegerin (OPG). Estrogen deficiency, glucocorticoid exposure, T-cell activation (eg, rheumatoid arthritis), and skeletal malignancies (eg, myeloma, metastases) enhance the ratio of RANKL to OPG and, thus, promote osteoclastogenesis, accelerate bone resorption, and induce bone loss. Moreover, alterations of the OPG/RANKL/RANK system have been implicated in vascular diseases. RANKL blockade (using OPG or RANK fusion proteins or RANKL antibodies) has prevented bone loss caused by osteoporosis, chronic inflammatory disorders, and malignant tumors in animal models and may emerge as a therapy in humans based on studies in postmenopausal osteoporosis, myeloma bone disease, and osteolytic metastases. This review summarizes the clinical implications of the OPG/RANKL/RANK system for bone and vascular diseases.

Author Affiliations: Departments of Gastroenterology, Endocrinology and Metabolism (Dr Hofbauer), and Cardiology (Dr Schoppet), Philipps-University, Marburg, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4-Dependent Pathway
Panizo et al.
Circ. Res. 2009;104:1041-1048.
ABSTRACT | FULL TEXT  

Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia
Graciolli et al.
Nephrol Dial Transplant 2009;24:1416-1421.
ABSTRACT | FULL TEXT  

The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients: Surveillance, Management and Prognostic Implications
TERPOS et al.
Anticancer Res 2009;29:1651-1657.
ABSTRACT | FULL TEXT  

The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer
Saidak et al.
Endocr. Rev. 2009;30:178-195.
ABSTRACT | FULL TEXT  

Aortic valve calcification: basic science to clinical practice
Akat et al.
Heart 2009;95:616-623.
ABSTRACT | FULL TEXT  

Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention
Parolari et al.
Eur. J. Cardiothorac. Surg. 2009;35:493-504.
ABSTRACT | FULL TEXT  

Bone-Vascular Axis in Chronic Kidney Disease: A Reality?
London
CJASN 2009;4:254-257.
FULL TEXT  

Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects: Effect of Treatment With B-Vitamins
Nenseter et al.
Stroke 2009;40:241-247.
ABSTRACT | FULL TEXT  

A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone
Andersen et al.
Am. J. Pathol. 2009;174:239-247.
ABSTRACT | FULL TEXT  

Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip
Samelson et al.
J. Clin. Endocrinol. Metab. 2008;93:1789-1795.
ABSTRACT | FULL TEXT  

Osteoprotegerin Lys3Asn Polymorphism and the Risk of Fracture in Older Women
Moffett et al.
J. Clin. Endocrinol. Metab. 2008;93:2002-2008.
ABSTRACT | FULL TEXT  

Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns et al.
Endocr. Rev. 2008;29:155-192.
ABSTRACT | FULL TEXT  

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide
Anastasilakis et al.
Eur J Endocrinol 2008;158:411-415.
ABSTRACT | FULL TEXT  

Bilateral Cavernous Internal Carotid Aneurysms in a Child with Juvenile Paget Disease and Osteoprotegerin Deficiency
Allen et al.
Am. J. Neuroradiol. 2008;29:7-8.
FULL TEXT  

Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality
Galusca et al.
J. Clin. Endocrinol. Metab. 2008;93:110-117.
ABSTRACT | FULL TEXT  

REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation
Tauchmanova et al.
J. Clin. Endocrinol. Metab. 2007;92:4536-4545.
ABSTRACT | FULL TEXT  

Bone Mineral Density in Adults with the Metabolic Syndrome: Analysis in a Population-Based U.S. Sample
Kinjo et al.
J. Clin. Endocrinol. Metab. 2007;92:4161-4164.
ABSTRACT | FULL TEXT  

Estrogen Therapy and Coronary-Artery Calcification
Hodis et al.
NEJM 2007;357:1252-1254.
FULL TEXT  

Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease
Kiechl et al.
Circulation 2007;116:385-391.
ABSTRACT | FULL TEXT  

Receptor Activator of NF-{kappa}B Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection
Miller et al.
J. Immunol. 2007;179:266-274.
ABSTRACT | FULL TEXT  

Musculoskeletal abnormalities in juvenile idiopathic arthritis--a 4-year longitudinal study
Roth et al.
Rheumatology (Oxford) 2007;46:1180-1184.
ABSTRACT | FULL TEXT  

Increased Osteoprotegerin Levels in Cushing's Syndrome Are Associated with an Adverse Cardiovascular Risk Profile
Dovio et al.
J. Clin. Endocrinol. Metab. 2007;92:1803-1808.
ABSTRACT | FULL TEXT  

Novel function of RANKL: eNOS activator
Fukumura and Jain
Blood 2007;109:1339-1340.
FULL TEXT  

Receptor activator of nuclear factor (NF)-{kappa}B ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice
Min et al.
Blood 2007;109:1495-1502.
ABSTRACT | FULL TEXT  

An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Heath et al.
Cancer Res. 2007;67:202-208.
ABSTRACT | FULL TEXT  

Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes
Cannata-Andia et al.
J. Am. Soc. Nephrol. 2006;17:S267-S273.
ABSTRACT | FULL TEXT  

Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer.
Li et al.
Cancer Res. 2006;66:4816-4825.
ABSTRACT | FULL TEXT  

Salivary biomarkers of existing periodontal disease: A cross-sectional study
Miller et al.
Journal of the American Dental Association 2006;137:322-329.
ABSTRACT | FULL TEXT  

Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status
Galluzzi et al.
Eur J Endocrinol 2005;153:879-885.
ABSTRACT | FULL TEXT  

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers and Eastell
J. Clin. Endocrinol. Metab. 2005;90:6323-6331.
ABSTRACT | FULL TEXT  

Recombinant Osteoprotegerin for Juvenile Paget's Disease
Cundy et al.
NEJM 2005;353:918-923.
ABSTRACT | FULL TEXT  

Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies
Hamerman
QJM 2005;98:467-484.
ABSTRACT | FULL TEXT  

Essential Role of {beta}-Catenin in Postnatal Bone Acquisition
Holmen et al.
J. Biol. Chem. 2005;280:21162-21168.
ABSTRACT | FULL TEXT  

Inhibition of Osteoporosis in Autoimmune Disease Prone MRL/Mpj-Faslpr Mice by N-3 Fatty Acids
Bhattacharya et al.
J. Am. Coll. Nutr. 2005;24:200-209.
ABSTRACT | FULL TEXT  

Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes
Mosheimer et al.
J. Clin. Endocrinol. Metab. 2005;90:2964-2971.
ABSTRACT | FULL TEXT  

GATA-6 Regulates Genes Promoting Synthetic Functions in Vascular Smooth Muscle Cells
Lepore et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:309-314.
ABSTRACT | FULL TEXT  

Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin-Osdoby
Circ. Res. 2004;95:1046-1057.
ABSTRACT | FULL TEXT  

Clinical and Basic Research Papers - July 2004 Selections
Seeman and Strewler
IBMS BoneKEy 2004;1:1-5.
FULL TEXT